Petros Pharmaceuticals Inc
petrospharma.comWhat Do They Do?
Develops a software platform intended to help pharmaceutical companies switch prescription drugs to nonprescription sales and guide consumers in choosing whether to use them.
10-K for FY2025, filed Apr 15, 2026Petros is pursuing the development of a proprietary integrated technology solutions platform (the “platform”) containing two components (i)…View ↗
Our SaaS platform is expected to serve as a digital hosting solution, offering pharmaceutical companies various features, such as secure…View ↗
In addition to the SaaS component, the platform is intended to incorporate SaMD capabilities, transforming traditional OTC medications into…View ↗
How Do They Make Money?
Petros intends to earn primarily from licensing its technology platform and creating customized online environments for partners. It expects no revenue until it completes development, obtains required regulatory approvals, and enters commercial arrangements.
10-K for FY2025, filed Apr 15, 2026
-
10-K for FY2024, filed Mar 31, 2025
FY2024 revenue by reportable segment ↗
$5.1M
-
10-K for FY2024, filed Mar 31, 2025
$5.1M ↗
| Segment | Share | Revenue |
|---|---|---|
|
Prescription Medications
|
38%
FY2021: 59%
|
Prescription Medications, FY2024
$2M Sources
|
|
Medical Devices
|
62%
FY2021: 41%
|
Medical Devices, FY2024
$3.2M Sources
|
Who Are Their Customers?
Targets pharmaceutical companies and exclusive over-the-counter licensees seeking to switch prescription drugs, as well as health-technology firms exploring digital platforms for over-the-counter treatments. It promotes the platform through industry conferences and business-development presentations.
10-K for FY2025, filed Apr 15, 2026Petros’ targeted customer base are pharmaceutical innovative label owners and exclusive OTC commercial licensees that are interested in…View ↗
Additionally, emerging companies in health tech present additional potential partners, particularly as they explore combining technology…View ↗
Petros has an established industry-wide network of prospective companies that may license our technology, if it is successfully developed…View ↗
Do Revenues Turn Into Profits?
No. It lost $14.3M in FY2024.
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$955.6KView ↗
- ▼ Now a loss
- vs $5.4M in Q2 FY2025
Shrinking. Revenue fell 47% in 4 years, from $9.6M in FY2020 to $5.1M in FY2024, about 14% a year.
Who Do They Compete With?
Competes with Astra Zeneca, Sanofi, and Idea Evolver
10-K for FY2025, filed Apr 15, 2026Currently, the Rx-to-OTC industry is driven by individual sponsors, each working independently to transition their products from…View ↗
Loading...
